The American Spectator

home
ADVERTISEMENT
The Public Policy
Print Email
Text Size

The Public Policy

Risky Business

Sen. Kennedy should push to liberalize drug approval standards.

(Page 2 of 2)

One study by economists from the University of Chicago, MIT, Biogen Idec Inc., and Westfield Capital looked at all 662 drugs approved from 1979 to 2002 and concluded that, even if every withdrawn drug provided no benefits at all, the faster pace of approvals beginning in the 1990s benefited patients with an extra 180,000 to 310,000 years of life — roughly three to five times greater than the worst case estimate of harms.

FDA is once again under enormous pressure to slow down reviews. But, since there is no way to rule out the possibility of even very serious side effects by testing a drug in a few thousand patients, the only way to ensure no withdrawals is to approve no new medicines.

That would be the real patient tragedy. Congress and the FDA need to skip the grandstanding and get serious about bringing safe and effective new treatments to market. For millions of Americans like Senator Kennedy, it truly is a matter of life or death.

Page:   12

topics:
Trade, NATO

About the Author

Gregory Conko is a senior fellow at the Competitive Enterprise Institute.

Letter to the Editor View all comments (3) |

Related Articles

More Articles by Gregory Conko

More Articles From The Public Policy

http://spectator.org/archives/2008/07/30/risky-business

ADVERTISEMENT

SPONSORED LINKS

FLASHBACK TO: 1995

Clip of the Day

Most Popular Articles

My Generation’s Disease

Benjamin Brophy | 5.17.13

The Liberal Union Behind the IRS

Jeffrey Lord | 5.16.13

Not Ready for Primetime Players

Daniel J. Flynn | 5.17.13

Assessing a Week of Scandal

Matt Purple | 5.17.13

Oops, Maybe Government is Tyrannical

Marta H. Mossburg | 5.17.13

From Bimbos to Benghazi

Jeffrey Lord | 5.9.13

The View From the Other Side

George H. Wittman | 5.17.13

ADVERTISEMENT